Volume 18, Number 1—January 2012
High Prevalence of Multidrug-Resistant Tuberculosis, Swaziland, 2009–2010
|Resistance pattern||No. (%) isolates resistant to isoniazid or rifampin,† n = 60||No. (%) isolates from case-patients with MDR TB, n = 122|
|No resistance to second-line drugs||54 (90.0)||72 (49.2)|
|Any resistance||6 (10.0)||62 (50.8)|
|Ethionamide||6 (10.0)||58 (47.5)|
|Specific resistance patterns|
|Ethionamide||6 (10.0)||50 (41.0)|
|Ethionamide + ofloxacin||0||6 (4.9)|
|Ethionamide + amikacin + capreomycin||0||1 (0.8)|
|Ethionamide + ofloxacin + amikacin + capreomycin||0||1 (0.8)|
*MDR, multidrug resistant; TB, tuberculosis; XDR, extensively drug resistant.
†Isolates from MDR TB patients excluded.
Page created: December 16, 2011
Page updated: December 16, 2011
Page reviewed: December 16, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.